ENEkaterina Konstantinovna Novikova

Ekaterina Konstantinovna Novikova

*This is an algorithmically generated author record based on publicly available information.

Ekaterina Konstantinovna Novikova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Scientific and theoretical foundations for the use of plant-derived polysaccharides as therapeutic and preventive agents

    by Daria Yurievna Makarova, Irina Evgenievna Kaukhova, Ekaterina Konstantinovna Novikova

    The role of plant-derived polysaccharides in human life is determined by their increasing impact on health and on preserving and enhancing human resources. Considering the multifunctional effects of polysaccharides on the human body, it appears appropriate to expand the scope of research on plant raw materials rich in these compounds. In this context, one approach involves engaging researchers in the search for new plant sources of polysaccharides, investigating their pharmacological effects, and developing new medicinal products based on them. The use of plant-derived polysaccharides as therapeutic and preventive agents is a relevant and increasingly important area in medical practice. Polysaccharides are high-molecular-weight compounds formed by condensation of monosaccharide residues and their derivatives linked by glycosidic bonds. Chemical modification, such as sulfation, is a potential strategy for improving physicochemical properties, as well as enhancing the bioavailability and stability of polysaccharides. The diversity of natural resources provides continuously renewable sources of plant-derived polysaccharides and creates broad opportunities for studying their pharmacological properties. The review includes fundamental and applied studies indexed in bibliographic databases (such as PubMed, ScienceDirect, Google Scholar, CyberLeninka, and eLibrary). The scientific data search was conducted using the keywords полисахариды растительного происхождения (plant-derived polysaccharides), фитопрепараты (phytopharmaceuticals), and химическая модификация полисахаридов (chemical modification of polysaccharides). This review presents an analysis of current data on plant-derived polysaccharides, highlighting the scientific and technological prerequisites for their application in the pharmaceutical industry in the near future. A comprehensive evaluation of plant-derived polysaccharides use as therapeutic and preventive agents incorporates perspectives from both Russian and international researchers. These findings indicate a pressing need for detailed investigation of the physicochemical properties of individual polysaccharides exhibiting pronounced immunomodulatory, antioxidant, and prebiotic activities.

  • Open Access

    Development of a technology for a combined hepatoprotective agent

    by I. E. Kauhova, O. N. Abrosimova, B. A. Perez, N. Y. Sipkina, E. K. Novikova, I. E. Smekhova, A. L. Marchenko

    Introduction. Hepatoprotectors are one of the broad drug groups used in complex therapy at different stages of liver damage. In clinical practice, hepatoprotective agents are used in form of individual or combined drugs. A combined drug is defined as a preparation containing two or more active biological substances that act together in the human body to prevent and treat diseases or to restore and maintain health. Combined drugs are used to increase the treatment effectiveness, reduce side effects, simplify medication intake, or help to treat multiple symptoms at the same time. Often the following well-known hepatotropic agents are most studied and used in combinations: essential phospholipids, glycyrrhizic acid, ursodeoxycholic acid and silymarin. It should be noted that although the pharmacological action of ursodeoxycholic acid and milk thistle preparations has been well studied, no technological research has been conducted to create combined medicines based on them. Aim. Development of a technology for a combined hepatoprotective agent in form of solid enteric-soluble gelatin capsules with granules containing ursodeoxycholic acid and milk thistle dry extract in form of a solid dispersion system as active substances. Material and methods. Ursodeoxycholic acid and the solid dispersion system of milk thistle dry extract are included as substances in the formulation of the combined hepatoprotective drug. Solid intestinal-soluble gelatin capsules were filled with granules containing a solid dispersion system of milk thistle dry extract and ursodeoxycholic acid using a ProFiller 3600 desktop manual capsule filling machine, capsule size "2". 3 series of solid gelatin capsules with granules were developed. The capsules standardization was carried out in accordance with the State Pharmacopoeia of the Russian Federation XV edition. The following indicators were determined: description, authenticity, quantitative content of the amount of flavolignans in terms of silybin, quantitative content of ursodeoxycholic acid, mass uniformity of dosage forms, disintegration and dissolution. Results and discussion. The granules formulation was developed by wet granulation, microcrystalline cellulose as disintegrator, magnesium stearate as lubricant, and 5 % aqueous solution of potato starch were used as excipients. The obtained formulations were compared in terms of quality and technological properties. It was found that granules containing microcrystalline cellulose have the best technological properties, such as weight loss during drying, hygroscopicity, bulk density, Carr index, Hausner coefficient, flowability. For capsules with granules, quality indicators were determined and standardized according to the POA (pharmacopeia official article) "Capsules" in terms of quality indicators: description, authenticity, quantitative content of the amount of flavonoids in terms of silybin, quantitative content of ursodeoxycholic acid, mass uniformity of dosage forms, disintegration and dissolution. When performing the "Dissolution" test, the release of silybin and UDCA was determined in 30, 45 and 60 minutes. The release of silybin was monitored by spectroscopy at a wavelength of λ = 289 nm and the release of ursodeoxycholic acid by high–performance liquid chromatography (HPLC) in accordance with the US pharmacopoeia, USP 44 – NF 39. It was determined that 89.0 ± 0.5 % of silybin was released in 45 minutes, during which time 97.0 ± 0.3 % of ursodeoxycholic acid was released. Conclusion. The granules formulation with a solid dispersion system of milk thistle dry extract and ursodeoxycholic acid has been developed. Microcrystalline cellulose is used as disintegrant, magnesium stearate as lubricant, and 5% aqueous solution of potato starch as binder. The technological properties of the granules and quality indicators are determined. The technology of intestinal-soluble capsules filled with granules has been developed. The quality indicators were determined and standardized according to quality indicators: description, authenticity, quantitative content of the amount of flavonoids in terms of silybin (by UV spectroscopy), quantitative content of ursodeoxycholic acid (by HPLC), mass uniformity of dosage forms, disintegration and dissolution. The releasing profiles of the active pharmaceutical substance from enteric capsules were studied and it was found that 89.0 ± 0.5 % of the amount of flavolignans in terms of silybin and 97.0 ± 0.3 % of ursodeoxycholic acid were released by 45 minutes, respectively, which meets the requirements of the State Pharmacopoeia of the Russian Federation XV edition.

  • Open Access

    Development of Technology of Phytosubstantiation of Silybum marianum L. Fruits as a Component of Complex Therapy of Liver Diseases

    by B. A. Peres, A. P. Procyuk, A. B. Zelencova, I. E. Kauhova, M. V. Aroyan, E. K. Novikova

    Разработка технологии получения фитосубстанции расторопши пятнистой плодов ( Silybum marianum L.) в качестве компонента комплексной терапии заболеваний печени


  • Development of the Composition and Technology of Tablets Based on Astragalus membranaceus (Fisch.) Bunge Dry Extract

    by M. V. Aroyan, D. E. Lohmatova, D. D. Vantorina, E. K. Novikova, I. E. Kaukhova, M. V. Nechaev

    Introduction. Human performance depends on external and internal factors. Of a number of external factors, the environmental aspect is one of the leading ones. Internal factors are interrelated with external ones. The latter include the general condition of the human body, as well as the normal functioning of individual systems and organs. It must be noted that the use of herbal drugs in order to prevent the development of pathologies caused by internal factors is rational. A number of plants contain substances that can improve performance by strengthening the cardiovascular system, normalizing the liver, adjusting daily rhythms, reducing stress. In this regard, the development of the composition and technology of drugs based on substances of plant origin does not lose relevance.Aim. Development of the composition of solid oral dosage form based on dry extract of Astragalus membranaceus (Fisch.) Bunge containing saponins.Materials and methods. As an object of research, a substance was used – dry extract of Astragalus membranaceus (Fisch.) Bunge, standardized in accordance with the requirements of SP XIV ed. Lactose monohydrate, calcium stearate, methylcellulose, corn starch, talc were used as excipients in the tablet technology. Under laboratory conditions, granulation was carried out by the wet mass extrusion method. A 3 % methylcellulose solution was used as the wetting reagent. Quality parameters of the final dosage form, tablets, were determined according to the methods described in SP XIV ed.Results and discussion. As a result of the conducted research, the composition of a solid oral dosage form based on a dry extract of Astragalus membranaceus (Fisch.) Bunge was proposed. The main quality indicators of the obtained dosage form are determined. A design quality specification has been developed for a drug.Conclusion. The present study proposed technology dry extract for Astragalus membranaceus (Fisch.) Bunge herb. Quality index of the obtained plant substance are determined. The composition and technology of tablets based on the dry extract of Astragalus membranaceus (Fisch.) Bunge herb have been developed. The main quality indicators of tablets based on the dry extract of Astragalus membranaceus (Fisch.) Bunge herb were determined. A draft quality specification of the resulting dosage form has been developed.


  • Open Access

    Development of Composition and Technology of Effervescent Tablets with Biologically Active Complex of Black Chokeberry (Aronia melanocarpa (Michx.) Elliott) Fruits

    by N. S. Pivovarova, O. N. Abrosimova, T. S. Shebitchenko, N. V. Sokrasnkina, A. A. Shmarova, E. K. Novikova, K. O. Sidorov

    Introduction. Actual use of plant raw materials in the production of medicines is caused by a variety of bioactive substance complexes in their composition. These drugs have a wide range of therapeutic effects and in this regard, the properties and compositions of various plant materials are currently being actively studied. Aronia melanocarpa (chokeberry) has been the focus of scientific research for many years to identify various healing properties, and in 2015 its fresh and dried fruits are presented as a plant raw material in the State Pharmacopoeia of the Russian Federation, XIV edition. The variety of biologically active substance complexes of Aronia melanocarpa fruit allows its use in different fields (food and pharmaceutical industries). For this reason, the development of the composition and technology of effervescent tablets containing a complex of biologically active substances and possessing the following advantages: rapid release of active ingredients, high rate of BAS assimilation, usability and pleasant flavor are of interest.Aim. The aim of the present study is to develop the composition and technology of effervescent tablets with a biologically active complex from dried Аronia melanocarpa fruits.Materials and methods. Extracts enriched with anthocyanins were obtained from dried chokeberry fruits. As excipients in the technology of effervescent tablets, sodium carbonate, tartaric acid, lactose monohydrate, povidone (Plasdone™ K-29/32), polyethylene glycol 6000 and aspartame were used. Under laboratory conditions, granules (acidic and basic) were obtained by the method of punching wet masses, where extract (granulate 1) and ethyl alcohol 96 % (granulate 2) were used as a moisturizer. Numerical indicators of medicinal plant raw materials, technological properties of granulate and tableting mass, as well as quality indicators of effervescent tablets were determined according to the methods described in the State Pharmacopoeia of the Russian Federation, XIV edition.Results and discussion. Numerical indicators of dry fruits of Aronia melanocarpa (crushing of raw materials and the content of foreign impurities, total ash in plant raw materials and ash insoluble in hydrochloric acid, content of extractives) were determined, and the good quality of the raw materials used in the subsequent stages of drug development was confirmed. An extract enriched with anthocyanins has been developed. The composition and technology of effervescent tablets with separate granulation of acidic and basic components has been developed. Extract and ethyl alcohol 96 % were used as moisturizers, and aspartame was used to improve taste characteristics. A draft specification for the quality indicators of effervescent tablets based on enriched extraction has been proposed.Conclusion. In the course of the research work, the numerical indicators of medicinal plant raw materials were determined and its quality was confirmed, which enabled its use for further extraction. Extraction conditions were chosen, extracts were obtained. Excipients have been selected, the composition and technology of effervescent tablets based on the extracts of Aronia melanocarpa fruits have been developed, a draft specification for effervescent tablets has been proposed in accordance with the requirements of the State Pharmacopoeia of the Russian Federation, XIV edition.


  • Open Access

    Determination of individual coumarin in a dry extract of Melilotus officinalis L.

    by M. V. Aroyan, Yu. E. Generalova, I. I. Terninko, I. E. Kaukhova, E. K. Novikova

    Introduction. Substances of plant origin exhibit a variety of pharmacological activity in combination with a relatively low toxicity and frequency of side effects. In this regard, a promising direction is the standardization of substances of plant origin in the development of new herbal medicinal products.Aim. Qualitative and quantitative determination of individual coumarin in a dry extract of Melilotus оfficinalis L.Materials and methods. A dry extract of the Melilotus officinalis L. was used as an object of research. Determination of individual coumarin was carried out by high-performance liquid chromatography.Results and discussion. As a result of the research, coumarin was identified by high performance liquid chromatography based on comparison of retention times of the sample with retention times of a standard sample of coumarin in the sample of dry extract under research. The coumarin contents in the dry extract was 0.642 ± 0.007 %.Conclusion. The data obtained on the qualitative and quantitative content of coumarin in the dry extract of Melilotus оfficinalis L. were used in the development of the draft version specification of quality indicators.